Advertisement

Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 600x60px
Document › Details

CRISPR Therapeutics AG. (10/4/17). "Press Release: CRISPR Therapeutics to Present at Investor Conferences in October". Zug & Cambridge, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Jefferies LLC
  Group Leucadia (Group)
Product Product  Chardan Gene Therapy Conference 2017 New York
Index terms Index term CRISPR Therapeutics–Leucadia: investor conference, 201710 supply service CRISPR presents at Jefferies Gene Technology Investor Summit in New York
  Index term 2 CRISPR Therapeutics–Chardan: investor conference, 201710 supply service CRISPR presents at Chardan Gene Therapy Conference in New York
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Brinzey, Chris (Westwicke Partners 201703)
     


CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., President of CRISPR Therapeutics, is scheduled to present at two upcoming Investor Conferences in October.

Event: Chardan Gene Therapy Conference
Date: Tuesday, October 10, 2017
Time: 2:00 PM EDT

Event: Jefferies Gene Technology Investor Summit
Date: Thursday, October 12, 2017
Time: 11:10 AM EDT


About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.


MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 chris.brinzey@westwicke.com

   
Record changed: 2017-10-16

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px